Evidence map›Paper›PMID 40435016›Full record

ArticlePloS one2025

AMD-FV: Adaptive margin loss and dual path network+ for deep face verification.

Zeeshan Ahmed Khan, Waqar Ahmed, Panos Liatsis

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zeeshan Ahmed KhanDepartment of Computer Science, School of Informatics, Xiamen University, Fujian, China.
Waqar AhmedDepartment of Computer Science, Khalifa University, Abu Dhabi, United Arab Emirates.ORCID https://orcid.org/0000-0001-5416-149X
Panos LiatsisDepartment of Computer Science, Khalifa University, Abu Dhabi, United Arab Emirates.ORCID https://orcid.org/0000-0002-5490-6030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Face verification is important in a variety of applications, for instance, access control, surveillance, and identification. Existing methods often struggle with the challenges of dataset imbalance and manual hyperparameter tuning. To address this, we propose the Adaptive Margin Loss and Dual Path Network+ (AMD-FV) for deep face verification. Two innovations are introduced, namely, Adaptive Margin Loss (AML) and Dual Path Network+ (DPN+). AML aims at automating the selection of margin and scale hyperparameters in large margin loss functions, thus, eliminating the need for manual tuning. Input dissimilarity information is used to estimate the margin, while the scale parameter is computed using the number of classes and AML's range. Next, DPN+ enhances the original Dual Path Network by redesigning the first block with a series of 3x3 convolutions, batch normalization, and ReLU activations, leveraging shared connections across layers, leading to increases in spatial resolution and computational cost efficiency, while maximizing the use of discriminative features. We present comprehensive experiments on five diverse face verification datasets (LFW, Megaface, IJB-B, CALFW, and CPLFW) to demonstrate the effectiveness of the proposed approach. The results show that AMD-FV outperforms state-of-the-art methods, achieving a verification accuracy of 99.75% on LFW, improving the True Acceptance Rate by 6% on IJB-B at a False Acceptance Rate of 0.001, compared to VGGFace2, and attaining a Rank-1 identification score of 92.16% on Megaface, surpassing the CosFace model by 9.44%.

Indexed as

Automated Facial RecognitionBiometric IdentificationFaceImage Processing, Computer-AssistedAlgorithmsDatabases, FactualHumans

Identifiers

PMID40435016
PMCPMC12118897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.